One of the world's leading research institutes, our scientists are working to advance understanding of biological processes at the molecular level - providing the knowledge needed to solve key problems in human health.

Heptares Therapeutics granted key patents for GPCR-Focused Drug Discovery Platform

Published on 17 December, 2014

Heptares Therapeutics, a leading G protein-coupled receptor (GPCR) structure-guided drug discovery company, has recently been granted multiple key patents in the USA. GPCRs are a superfamily of drug receptors linked to a wide range of human diseases and Heptares was founded in 2007 to develop and commercialise pioneering research from the LMB and the National Institute of Medical Research (NIMR) to find new medicines targeting GPCRs. Sir John Saville presented the inventors with a memento to mark the award of these key patents for the GPCR-focused drug discovery platform. More…